Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Orphazyme. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Orphazyme's earnings available for a low price, and how does
this compare to other companies in the same industry?
Orphazyme is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Orphazyme is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Orphazyme's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Ms. Kim Stratton has been Chief Executive Officer of Orphazyme A/S since October 1, 2019. Ms. Stratton has been a Director at Vifor Pharma AG since May 08, 2019. Ms. Stratton was the Head of International Commercial at Shire plc. since July 1, 2016. Ms. Stratton joined Shire in 2013. Ms. Stratton served as the Global Head of Group Country Management and External Affairs at Novartis AG and Novartis Vaccines and Diagnostics, Inc. since February 8, 2010. Ms. Stratton leads the Respiratory and Dermatology franchises for the U. S. business and help drive sales in the world's largest pharmaceutical market. Ms. Stratton served as the Head of the Country Pharma Organization and Country President at Novartis in Portugal beginning in April 2006. After joining Novartis in 1998, Ms. Stratton has held positions of increasing responsibility in the Pharmaceuticals Division and country organizations. She served as Vice President of Respiratory & Dermatology Franchise and Global Head of Respiratory & Dermatology Franchise in Basel, Switzerland at Novartis Pharma AG. She worked at Novartis in the UK as a Sales Director and also held Commercial Director and Chief Operating Officer positions in the UK. Ms. Stratton also held a variety of commercial roles spanning several disease areas prior to joining Novartis. At AstraZeneca, she served as the Head of the UK Respiratory Business Unit and served as the Head of HIV Business Unit and worked in both Oncology and Cardiovascular as Head of Marketing at Bristol-Myers Squibb. She serves as a Member of Europe Advisory Board of Catalyst Inc. Her career started in Australia as a Sales Representative at Glaxo. She has been a Director of Novozymes A/S since February 22, 2017. Ms. Stratton studied Nursing in Sydney, Australia. She qualified as a State Registered Nurse at the Royal North Shore Hospital.
Insufficient data for Kim to compare compensation growth.
Insufficient data for Kim to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Orphazyme management team is about average.
Chief Executive Officer
Co-Founder & Chief Scientific Officer
Chief Financial Officer
Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Orphazyme board of directors is about average.
Board of Directors
Independent Deputy Chairman
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of orphan protein-misfolding diseases. It focuses on developing therapies for diseases caused by misfolding of proteins and lysosomal dysfunction. The company’s lead candidate, Arimoclomol, is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. It also focuses on developing a series of heat-shock protein amplifying drugs. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.